Catalytic Performance of CuZnAl Hydrotalcite-Derived Materials in the Continuous-Flow Chemoselective Hydrogenation of 2-Methyl-2-pentanal toward Fine Chemicals and Pharmaceutical Intermediates.

Hydrotalcite-derived materials are eco-friendly, cheap, and efficient catalysts of different reactions. However, their application in liquid-phase hydrogenation could be more extensive. Hence, this work concerns the application of three hydrotalcite-derived materials with different CuZnAl molar ratios in the liquid-phase continuous-flow hydrogenation of 2-methyl-2-pentenal (MPEA) at a wide range of temperature (298-378 K) and pressure (1 × 10-6 × 10 Pa).

Numerical model of human head phantom to ensure dosimetry of dose components for boron neutron capture therapy.

Extremely important aspects of the boron neutron capture therapy are, first of all, administering to the patient a boron compound that selectively reaches the neoplastic cells, and in the second step, the verification of the irradiation process. This paper focuses on the latter aspect, which is the detailed dosimetry of the processes occurring after the reaction of thermal neutrons with the boron-10 isotope. The results of computer simulations with the use of a new type of human head phantom filled with a polymer dosimetric gel will be presented in this article.

Transition Metal-Promoted Mg-Fe Mixed Oxides for Conversion of Ethanol to Valuable Products.

The conversion of ethanol into petrochemicals, such as ethyl and butyl acetate, butanol, hexanol, and so forth was studied. The conversion was catalyzed by Mg-Fe mixed oxide modified with a second transition metal (Ni, Cu, Co, Mn, or Cr). The main aim was to describe the influence of second transition metal on (i) the catalyst itself and (ii) reaction products such as ethyl acetate, butanol, hexanol, acetone, and ethanal.

Human and mouse PD-L1: similar molecular structure, but different druggability profiles.

In the development of PD-L1-blocking therapeutics, it is essential to transfer initial findings into proper animal models. Classical immunocompetent mice are attractive due to high accessibility and low experimental costs. However, it is unknown whether inter-species differences in PD-L1 sequence and structure would allow for human-mouse cross applications.

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

Immune checkpoint blockade is one of the most promising strategies of cancer immunotherapy. However, unlike classical targeted therapies, it is currently solely based on expensive monoclonal antibodies, which often inflict immune-related adverse events. Herein, we propose a novel small-molecule inhibitor targeted at the most clinically relevant immune checkpoint, PD-1/PD-L1.